Antiinflammatory functions of p38 in mouse models of rheumatoid arthritis: Advantages of targeting upstream kinases MKK-3 or MKKk-6

Arthritis and Rheumatism

Volumn 64, Issue 9, 2012, Pages 2887-2895

  Guma, Monica ^a   Hammaker, Deepa ^a   Topolewski, Katharyn ^a   Corr, Maripat ^a   Boyle, David L ^a   Karin, Michael ^a   Firestein, Gary S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; PROTEIN P38 ALPHA; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; GENE DELETION; MACROPHAGE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; SYNOVITIS; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATION; INTERFERON-GAMMA; JOINTS; MACROPHAGES; MAP KINASE KINASE 3; MAP KINASE KINASE 6; MICE; MICE, KNOCKOUT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; SPLEEN; SYNOVIAL MEMBRANE;

EID: 84865663791     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34489     Document Type: Article

References (35)

1. Firestein GS,. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61.
2. Thalhamer T, McGrath MA, Harnett MM,. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008; 47: 409-14.
3. Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal- regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2501-12.
4. Schett G, Zwerina J, Firestein G,. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 2008; 67: 909-16.
5. Sweeney SE, Firestein GS,. Mitogen activated protein kinase inhibitors: where are we now and where are we going? Ann Rheum Dis 2006; 65 Suppl III: iii83-8.
6. Hammaker D, Firestein GS,. "Go upstream, young man": lessons learned from the p38 saga. Ann Rheum Dis 2010; 69 Suppl I: i77-82.
7. Kumar S, Boehm J, Lee JC,. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003; 2: 717-26.
8. Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, DeLora P, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009; 60: 335-44.
9. Genovese MC,. Inhibition of p38: has the fat lady sung? [editorial]. Arthritis Rheum 2009; 60: 317-20.
10. Damjanov N, Kauffman RS, Spencer-Green GT,. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009; 60: 1232-41.
11. Cohen P,. Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol 2009; 21: 317-24.
12. Kim C, Sano Y, Todorova K, Carlson BA, Arpa L, Celada A, et al. The kinase p38α serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat Immunol 2008; 9: 1019-27.
13. Ananieva O, Darragh J, Johansen C, Carr JM, McIlrath J, Park JM, et al. The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nat Immunol 2008; 9: 1028-36.
14. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis D,. Organ-specific disease provoked by systemic autoimmunity. Cell 1996; 87: 811-22.
15. Nishida K, Yamaguchi O, Hirotani S, Hikoso S, Higuchi Y, Watanabe T, et al. p38α mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload. Mol Cell Biol 2004; 24: 10611-20.
16. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I,. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 1999; 8: 265-77.
17. Wysk M, Yang DD, Lu HT, Flavell RA, Davis RJ,. Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for tumor necrosis factor-induced cytokine expression. Proc Natl Acad Sci U S A 1999; 96: 3763-8.
18. Tanaka N, Kamanaka M, Enslen H, Dong C, Wysk M, Davis RJ, et al. Differential involvement of p38 mitogen-activated protein kinase kinases MKK3 and MKK6 in T-cell apoptosis. EMBO Rep 2002; 3: 785-91.
19. Guma M, Ronacher L, Liu-Bryan R, Takai S, Karin M, Corr M,. Caspase 1-independent activation of interleukin-1β in neutrophil-predominant inflammation. Arthritis Rheum 2009; 60: 3642-50.
20. Shigeoka AA, Kambo A, Mathison JC, King AJ, Hall WF, da Silva Correia J, et al. Nod1 and Nod2 are expressed in human and murine renal tubular epithelial cells and participate in renal ischemia reperfusion injury. J Immunol 2010; 184: 2297-304.
21. min/+ mice. Nat Med 2010; 16: 665-70.
22. Inoue T, Boyle DL, Corr M, Hammaker D, Davis RJ, Flavell RA, et al. Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis. Proc Natl Acad Sci U S A 2006; 103: 5484-9.
23. Yoshizawa T, Hammaker D, Boyle DL, Corr M, Flavell R, Davis R, et al. Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expression. J Immunol 2009; 183: 1360-7.
24. Rosengren S, Firestein GS, Boyle DL,. Measurement of inflammatory biomarkers in synovial tissue extracts by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2003; 10: 1002-10.
25. Boyle DL, Rosengren S, Bugbee W, Kavanaugh A, Firestein GS,. Quantitative biomarker analysis of synovial gene expression by real-time PCR. Arthritis Res Ther 2003; 5: R352-60.
26. Page TH, Brown A, Timms EM, Foxwell BM, Ray KP,. Inhibitors of p38 suppress cytokine production in rheumatoid arthritis synovial membranes: does variable inhibition of interleukin-6 production limit effectiveness in vivo? Arthritis Rheum 2010; 62: 3221-31.
27. Solomon S, Rajasekaran N, Jeisy-Walder E, Snapper SB, Illges H,. A crucial role for macrophages in the pathology of K/B x N serum-induced arthritis. Eur J Immunol 2005; 35: 3064-73.
28. Gierut A, Perlman H, Pope RM,. Innate immunity and rheumatoid arthritis. Rheum Dis Clin North Am 2010; 36: 271-96.
29. Mulherin D, FitzGerald O, Bresnihan B,. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996; 39: 115-24.
30. Wijbrandts CA, Vergunst CE, Haringman JJ, Gerlag DM, Smeets TJ, Tak PP,. Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: implications for use of synovial sublining macrophages as a biomarker. Arthritis Rheum 2007; 56: 3869-71.
31. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo [published erratum appears in Arthritis Rheum 2012;64:1487]. Arthritis Rheum 2009; 60: 1895-905.
32. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58: 3309-18.
33. Inoue T, Hammaker D, Boyle DL, Firestein GS,. Regulation of p38 MAPK by MAPK kinases 3 and 6 in fibroblast-like synoviocytes. J Immunol 2005; 174: 4301-6.
34. Hammaker D, Topolewski K, Edgar M, Yoshizawa T, Fukushima A, Boyle DL, et al. Decreased collagen-induced arthritis severity and adaptive immunity in MKK-6-deficient mice. Arthritis Rheum 2012; 64: 678-87.
35. Sorkin LS, Boyle DL, Hammaker D, Herman DS, Vail E, Firestein GS,. MKK3, an upstream activator of p38, contributes to formalin phase 2 and late allodynia in mice. Neuroscience 2009; 162: 462-71.